In this sense, specific molecular markers such as Isocitrate-Dehydrogenase (IDH) mutations, loss of transcriptional regulator Alpha-thalassemia mental retardation X-linked protein (ATRX) and codeletions of chromosomes 1p/19q have been routinely applied for optimized glioma characterization since 2016 (Louis et al., 2007a,b, 2016). This evidence concerns the gene IDH1 and glioma.